Cargando…
The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence
Rivaroxaban is a direct, oral factor Xa inhibitor that is used for the prevention and treatment of various thromboembolic disorders. Several preclinical and clinical studies have utilized specific molecules as biomarkers to investigate the potential role of rivaroxaban beyond its anticoagulant activ...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110699/ https://www.ncbi.nlm.nih.gov/pubmed/36746885 http://dx.doi.org/10.1007/s11239-023-02776-z |